Intech Biopharm (6461) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 益得

Intech Biopharm (6461) reported revenue of NT$4,000 for Oct 2026, -99.7% year on year and -99.9% from the previous month. Revenue for Jan–Oct 2026 was NT$49.5 million (-52.5% year on year).

In Oct 2026, it ranked No. 155 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$1.5 million24/10Nov 2024 NT$3.3 millionDec 2024 NT$6.3 millionJan 2025 NT$1.5 millionFeb 2025 NT$5.8 million25/02Mar 2025 NT$328,000Apr 2025 NT$3.9 millionMay 2025 NT$13.4 millionJun 2025 NT$70.5 million25/06Jul 2025 NT$709,000Aug 2025 NT$470,000Sep 2025 NT$6.1 millionOct 2025 NT$1.6 million25/10Nov 2025 NT$533,000Dec 2025 NT$2.7 millionJan 2026 NT$7.4 millionFeb 2026 NT$1.6 million26/02Mar 2026 NT$8.6 millionApr 2026 NT$5.6 millionMay 2026 NT$7.1 millionJun 2026 NT$6.2 million26/06Jul 2026 NT$211,000Aug 2026 NT$5.7 millionSep 2026 NT$7.2 millionOct 2026 NT$4,00026/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$4,000-99.7%-99.9%
Sep 2026NT$7.2 million+18.1%+27.5%
Aug 2026NT$5.7 million+1,103.0%+2,579.6%
Jul 2026NT$211,000-70.2%-96.6%
Jun 2026NT$6.2 million-91.3%-13.4%
May 2026NT$7.1 million-47.1%+28.0%
Apr 2026NT$5.6 million+43.7%-35.5%
Mar 2026NT$8.6 million+2,527.1%+436.2%
Feb 2026NT$1.6 million-72.4%-78.3%
Jan 2026NT$7.4 million+394.2%+169.9%
Dec 2025NT$2.7 million-56.7%+413.9%
Nov 2025NT$533,000-84.1%-65.7%
Oct 2025NT$1.6 million+4.4%-74.6%
Sep 2025NT$6.1 million+22,496.3%+1,198.1%
Aug 2025NT$470,000-91.2%-33.7%
Jul 2025NT$709,000-78.3%-99.0%
Jun 2025NT$70.5 million+8,430.9%+424.5%
May 2025NT$13.4 million+679.7%+247.4%
Apr 2025NT$3.9 million+45.5%+1,079.0%
Mar 2025NT$328,000-95.4%-94.4%
Feb 2025NT$5.8 million+246.9%+289.8%
Jan 2025NT$1.5 million-74.6%-76.3%
Dec 2024NT$6.3 million+2,056.7%+88.9%
Nov 2024NT$3.3 million-16.4%+125.2%
Oct 2024NT$1.5 million+29.2%+5,403.7%

Jan–Oct 2026 cumulative: NT$49.5 million (-52.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Intech Biopharm vs PEC / Intech Biopharm vs Lotus Pharm / Intech Biopharm vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本月及本年較去年同期減少,主要因經銷商備貨減少以及去年認列海思科完成合約之技術服務收入6,804萬所致。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16